ArticleMolecular cancer therapeutics2022

Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.

Jennifer R Diamond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.